Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.
暂无分享，去创建一个
L. Joosten | C. Dinarello | T. Jansen | C. Scribner | C. Marchetti | Isak W. Tengesdal | M. Janssen | V. Klück | M. C. Cleophas | M. Efdé | K. Schraa | A. Comarniceanu | Damaris B. Skouras | D. Skouras | M. Efde